You are here

Our science / Clinical Trials / Find a Trial / NCT00445315

A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients

Back to Search Print Save as PDF Bookmark Trial

NCT00445315

Last updated on March 11, 2019
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Bruxelles, , 1070 Belgium
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hepatitis C
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-65 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- HCV RNA ≥ 100,000 IU/mL at screening

- Genotype 1a or 1b

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Current or prior treatment with IFN and/or RBV

- Evidence of decompensated liver disease

NCT00445315
Pfizer
Completed
A Phase 1 Study Of PF-00868554 In Hepatitis C Virus (HCV) Positive Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Advanced Search

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now